Mendelian randomization and estimation of treatment efficacy for chronic diseases

Area of Science:

• Epidemiology
• Genetics
• Clinical Trials

Background:

• Therapies have revolutionized noncommunicable chronic disease (NCDC) management.
• Recent randomized controlled trials (RCTs) show unexpected lower benefits for NCDC therapies.
• Observational analyses of RCT data have not resolved these discrepancies.

Purpose of the Study:

• To propose Mendelian randomization (MR) as a complementary approach to RCTs for understanding NCDC therapies.
• To enhance etiological understanding of current therapies and identify treatments for NCDCs resistant to current treatments.

Main Methods:

• Utilizes Mendelian randomization (MR) to estimate causal effects from observational or trial data.
• Compares the mechanistic insights gained from MR with the efficacy assessments from RCTs.
• Suggests integrating MR studies into the design phase of RCTs.

Main Results:

• RCTs assess therapy efficacy but often lack mechanistic pathway confirmation.
• MR studies assess causal effects on mechanistic pathways, not direct therapy efficacy.
• Combining RCTs and MR provides complementary information for improved etiological understanding.

Conclusions:

• Integrating MR into RCT design can enhance understanding of therapy mechanisms.
• This integrated approach can improve the search for novel therapies for treatment-resistant NCDCs.
• MR offers a valuable tool for dissecting causal relationships in chronic disease research.